Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Pharmacology

• Publication date

  2018-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000492936PMID 30384375
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study

  2017cited by this paper
• Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors.

  2017cited by this paper
• The G Protein-Coupled Receptor UT of the Neuropeptide Urotensin II Displays Structural and Functional Chemokine Features

  2017cited by this paper
• Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-κB pathway in tumor-bearing nude mice.

  2012cited by this paper
• Renal impairment, hypertension and plasma urotensin II.

  2011cited by this paper
• Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects

  2009cited by this paper
• Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II.

  2008cited by this paper
• Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction.

  2008cited by this paper
• The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats

  2006cited by this paper
• The role of urotensin II in cardiovascular and renal physiology and diseases

  2006cited by this paper
• Architecture of the human urotensin II receptor: comparison of the binding domains of peptide and non-peptide urotensin II agonists.

  2005cited by this paper
• Urotensin II: Its Function in Health and Its Role in Disease

  2005cited by this paper
• Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries.

  2004cited by this paper
• Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

  2004cited by this paper
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cited by this paper
• Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.

  2004cited by this paper
• Cardiovascular actions of human urotensin II—considerations for hypertension

  2004cited by this paper
• Urotensin II and cardiovascular diseases.

  2004cited by this paper
• Plasma concentration of urotensin II is raised in hypertension

  2004cited by this paper
• Urotensin II, a novel peptide in central and peripheral cardiovascular control.

  2004cited by this paper
• Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy.

  2004cited by this paper
• Urotensin II: the old kid in town.

  2004cited by this paper
• Effect of human urotensin-II infusion on hemodynamics and cardiac function.

  2003cited by this paper
• Increased plasma urotensin II levels in patients with diabetes mellitus.

  2003cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

  2002cited by this paper
• Is urotensin‐II the new endothelin?

  2002cited by this paper
• Urotensin II evokes potent vasoconstriction in humans in vivo

  2002cited by this paper
• Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

  2001cited by this paper
• Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells.

  2001cited by this paper
• Urotensin II: a new mediator in cardiopulmonary regulation?

  2001cited by this paper
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Effects of Urotensin II in Human Arteries and Veins of Varying Caliber

  2001cited by this paper
• Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1

  2000cited by this paper
• Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat

  2000cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party

  1995cited by this paper
• Teleostean urophysis: urotensin II and ion transport across the isolated skin of a marine teleost.

  1979cited by this paper
• [Serum creatinine determination without protein precipitation].

  1972cited by this paper
• A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts.

  1969cited by this paper

• The urotensin II receptor triggers an early meningeal response and a delayed macrophage-dependent vasospasm after subarachnoid hemorrhage in male mice

  2024cites this paper
• Urotensin receptor acts as a novel target for ameliorating fasting-induced skeletal muscle atrophy.

  2022cites this paper
• Targeting of G-protein coupled receptors in sepsis.

  2020cites this paper
• Towards Targeting the Urotensinergic System: Overview and Challenges.

  2019cites this paper